Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adagio Medical Holdings (ADGM) Cash from Operations (2023 - 2026)

Adagio Medical Holdings (ADGM) reported Cash from Operations of 4100000.0 for Q1 2026, up 43.06% year-over-year from 2866019.42 in Q1 2025, and up 0.92% on a QoQ basis from 4138000.0 in Q4 2025.

Adagio Medical Holdings (ADGM) has 4 years of Cash from Operations data on file, last reported at 4100000.0 in Q1 2026.

  • Quarterly Cash from Operations rose 43.06% year-over-year to 4100000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 21838000.0 (up 18.47% YoY) and the FY2025 annual result came in at 19014000.0, down 41.17% from the prior year.
  • Cash from Operations rose to 4100000.0 in Q1 2026 per ADGM's latest filing, from 4138000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 4100000.0 in Q1 2026 and bottomed at 7200000.0 in Q1 2025.
  • The 4-year median for Cash from Operations is 6484000.0 (2024), against an average of 6016142.86.
  • The widest annual swing landed in 2025, when Cash from Operations retreated 7.46%; it then surged 43.06% in 2026.
  • Tracing ADGM's Cash from Operations over 4 years: stood at 7091000.0 in 2023, then climbed by 9.74% to 6400000.0 in 2024, then surged by 35.34% to 4138000.0 in 2025, then increased by 0.92% to 4100000.0 in 2026.
  • Per Business Quant, the three latest ADGM Cash from Operations figures stand at 4100000.0 (Q1 2026), 4138000.0 (Q4 2025), and 7200000.0 (Q1 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Operations (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 1.32 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn 581.00 Mn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn 2.74 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn 348.00 Mn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn 43.80 Mn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn 220.10 Mn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn 525.60 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn 290.00 Mn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn 335.40 Mn
10 Adagio Medical Holdings 16.86 Mn 3.95 Mn - -4.10 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -4.10 Mn
Mar 31, 2026 -4.10 Mn
Dec 31, 2025 -4.14 Mn
Dec 31, 2025 -4.14 Mn
Mar 31, 2025 -7.20 Mn
Mar 31, 2025 -7.20 Mn
Sep 30, 2024 -6.40 Mn
Sep 30, 2024 -6.40 Mn
Jun 30, 2024 -6.48 Mn
Jun 30, 2024 -6.48 Mn
Mar 31, 2024 -6.70 Mn
Mar 31, 2024 -6.70 Mn
Dec 31, 2023 -7.09 Mn
Dec 31, 2023 -7.09 Mn